The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The proglucagon gene encodes multiple structurally related peptides with overlapping actions promoting the absorption and assimilation of ingested energy. Notably, glucagon has been developed pharmaceutically to treat hypoglycemia, and glucagon-like peptide-1 (GLP-1) receptor agonists are used for the therapy of type 2 diabetes and obesity. Here I describe the discovery of glucagon-like peptide-2 (GLP-2), a 33 amino acid peptide cosecreted together with GLP-1 from gut endocrine cells. GLP-2 was found to exhibit robust intestinal growth-promoting activity, following serendipitous observations that proglucagon-producing tumors induced intestinal growth in mice. Key developments in the pharmaceutical development of GLP-2 included the cloning of the GLP-2 receptor, and the recognition of the importance of dipeptidyl peptidase-4 as a critical determinant of GLP-2 bioactivity. A therapeutic focus on short bowel syndrome, a serious medical disorder with compelling unmet medical need, enabled the pharmaceutical development of a simple GLP-2 analogue, teduglutide, suitable for once daily administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationHamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Exon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
Jeppesen, P. B., Pertkiewicz, M., Messing, B., Iyer, K., Seidner, D. L., O'keefe, S. J. D., Forbes, A., Heinze, H., & Joelsson, B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.007 · Cited by 505
Intestinal growth-promoting properties of glucagon-like peptide-2 in mice
Tsai, C. H., Hill, M., Asa, S. L., Brubaker, P. L., & Drucker, D. J. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.1.e77 · Cited by 319
Self-citationGlucagon physiology and pathophysiology
Sherwood, L. M., Parris, E. E., & Unger, R. H. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108192850806 · Cited by 267
Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon
Heinrich, G., Gros, P., & Habener, J. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89859-3 · Cited by 207
HEINRICH, G., GROS, P., LUND, P. K., BENTLEY, R. C., & HABENER, J. F. (1984) · Endocrinology · doi:10.1210/endo-115-6-2176 · Cited by 158
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Fuchs, S., Yusta, B., Baggio, L. L., Varin, E. M., Matthews, D., & Drucker, D. J. (2020) · JCI Insight · doi:10.1172/jci.insight.136907 · Cited by 29
Self-citationBuilding gut from scratch — progress and update of intestinal tissue engineering
Tullie, L., Jones, B. C., De Coppi, P., & Li, V. S. W. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00586-x · Cited by 27
Metadata
- Authors
- Drucker, D. J.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-03-01
- Volume
- 2
- Issue
- 2
- Pages
- 134-142
- ISSN
- 2575-9108 (ISSN-L)
- OpenAlex
- W2918255808
- Cited by
- 51
- References
- 10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.